Silence Therapeutics PLC Sponsored ADR

SLN Healthcare Biotechnology

Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.

8.68 0.67 −7.17%
Market cap
$581.1M
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
2/9
Altman Z
−4.82
Beneish M
45.78
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Net Income
(59.95) (75.04) (88.61) (64.54)

+8 more TTM periods

Depreciation & Amortization
0.48 0.52 0.56 0.58
Non Cash Items (Other)
2.92 11.00 15.63 8.46
Accounts Receivable Change
— — 1.99 —
Accounts Payable Change
(1.44) (8.87) (4.08) (2.19)
Change in other assets and liabilities
15.64 5.80 13.21 (13.87)
Operating Cash Flow
(42.26) (65.56) (62.27) (72.46)
Capital expenditures
— — (0.05) (0.12)
Short Term Investments Change (Net)
(89.52) — — —
Long-Term Investments Change (Net)
— (303.29) (378.03) —
Other investing activities
231.29 167.22 118.48 210.76
Investing cash flow
72.89 6.39 (47.99) 71.47
Equity Repurchase (Common, Net)
0.00 — 0.02 (0.08)
Financing cash flow
0.00 — 0.02 (0.08)
Exchange Rate Adjustment
(0.31) (0.05) 0.20 0.17
Change in Cash
30.32 (59.23) (110.05) (0.91)
Beginning Cash
11.28 11.28 121.33 121.33
Ending Cash
41.59 (47.95) 11.28 120.42
Stock Based Compensation
6.20 6.98 8.07 12.14
Dividends Paid (Common)
0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
14.29 (2.05) 10.16 (16.96)
Investments Change (Net)
(233.23) (303.29) (378.03) —
Issuance/Purchase of Shares
0.00 — 0.02 (0.08)

Fold the line items

In millions of $ except per-share values · columns are period end dates